Virginie Avrillon

774 total citations
34 papers, 153 citations indexed

About

Virginie Avrillon is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Virginie Avrillon has authored 34 papers receiving a total of 153 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Pulmonary and Respiratory Medicine, 16 papers in Oncology and 5 papers in Molecular Biology. Recurrent topics in Virginie Avrillon's work include Lung Cancer Treatments and Mutations (19 papers), Lung Cancer Diagnosis and Treatment (12 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Virginie Avrillon is often cited by papers focused on Lung Cancer Treatments and Mutations (19 papers), Lung Cancer Diagnosis and Treatment (12 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Virginie Avrillon collaborates with scholars based in France, United States and United Kingdom. Virginie Avrillon's co-authors include M. Pérol, L. Gérinière, Pierre-Jean Souquet, S. Couraud, Béatrice Fervers, Laure Folliet, Aurélie Swalduz, Gaëlle Fossard, Barbara Charbotel and M. Locatelli-Sanchez and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Virginie Avrillon

27 papers receiving 150 citations

Peers

Countries citing papers authored by Virginie Avrillon

Since Specialization

Citations

This map shows the geographic impact of Virginie Avrillon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Virginie Avrillon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Virginie Avrillon more than expected).

Fields of papers citing papers by Virginie Avrillon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Virginie Avrillon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Virginie Avrillon. The network helps show where Virginie Avrillon may publish in the future.

Co-authorship network of co-authors of Virginie Avrillon

This figure shows the co-authorship network connecting the top 25 collaborators of Virginie Avrillon. A scholar is included among the top collaborators of Virginie Avrillon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Virginie Avrillon. Virginie Avrillon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	208P: Pathological response after neoadjuvant chemotherapy (chemo) and nivolumab (NIVO) in resectable non-small cell lung cancer (NSCLC): Initial results from a French multicenter real-world (rw) retrospective study 2025 ·Journal of Thoracic Oncology ·(unknown), Quentin Thomas, B. Godbert, (unknown), (unknown), Virginie Avrillon, Olivier Bylicki, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Xavier Quantin, (unknown), Francesca Lucibello, Matthieu Carton	0
2	Anti-IL-6R Ab tocilizumab to treat paraneoplastic inflammatory syndrome of solid cancers 2025 ·ESMO Open ·Jean‐Yves Blay, (unknown), Armelle Dufresne, (unknown), Virginie Avrillon, Souad Assaad, C. Decroisette, Bénédicte Mastroïanni, (unknown), (unknown), (unknown), Pierre Méeus, Aurélie Dutour, Marie Castets, M. Pérol, Pierre-Étienne Heudel	0
3	Survival of bronchopulmonary cancers according to radon exposure 2024 ·Frontiers in Public Health ·(unknown), Olivia Pérol, (unknown), (unknown), Thomas Coudon, (unknown), Nicolas Foray, (unknown), Jérôme Fayette, (unknown), Aurélie Swalduz, (unknown), Pierre Saintigny, (unknown), (unknown), Frédéríc Gomez, Virginie Avrillon, M. Pérol, Barbara Charbotel, Béatrice Fervers	1
4	Occupational asbestos exposure and survival among lung cancer patients 2023 ·Lung Cancer ·(unknown), Olivia Pérol, M. Pérol, Virginie Avrillon, (unknown), Jérôme Fayette, (unknown), Aurélie Swalduz, (unknown), Jean‐Yves Blay, Eve‐Marie Neidhardt, Pierre Saintigny, (unknown), (unknown), Delphine Praud, Barbara Charbotel, Béatrice Fervers	10
5	Survival and risk of COVID-19 after SARS-COV-2 vaccination in a series of 2391 cancer patients 2022 ·European Journal of Cancer ·Pierre-Étienne Heudel, Bertrand Favier, (unknown), Souad Assaad, (unknown), Olivier Trédan, Thomas Bachelot, I. L. Ray-Coquard, (unknown), (unknown), Bénédicte Mastroïanni, Virginie Avrillon, Anne‐Sophie Michallet, Philippe Zrounba, Sylvie Chabaud, David Pérol, Jean‐Yves Blay	13
6	Nationwide Real-Life Safety and Treatment Exposure Data on Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III, Locally Advanced, Non-small Cell Lung Cancer: Analysis of Patients Enrolled in the French Early Access Program 2022 ·Lung ·Virginie Avrillon, Catherine Daniel, Pierre Boisselier, C. Le Péchoux, C. Chouaïd	10
7	High Circulating Sonic Hedgehog Protein Is Associated With Poor Outcome in EGFR-Mutated Advanced NSCLC Treated With Tyrosine Kinase Inhibitors 2021 ·Frontiers in Oncology ·Paul Takam Kamga, Aurélie Swalduz, Adrien Costantini, Catherine Julié, (unknown), M. Pérol, Virginie Avrillon, Sandra Ortiz‐Cuaran, Pierre Saintigny, Etienne Giroux‐Leprieur	3
8	Response to the Combination of Osimertinib, Dabrafenib, and Trametinib in Leptomeningitis From EGFR-Mutant NSCLC With Acquired BRAF V600E Mutation: A Case Report 2021 ·JTO Clinical and Research Reports ·(unknown), Aurélie Swalduz, (unknown), Adrien Buisson, Virginie Avrillon, Bénédicte Mastroïanni, M. Pérol	7
9	1349P Lorlatinib for advanced ROS1+ non-small cell lung cancer (NSCLC): Efficacy and safety data from IFCT-1803 LORLATU expanded access program (EAP) cohort 2020 ·Annals of Oncology ·Nicolas Girard, (unknown), M. Duruisseaux, Virginie Avrillon, Benoît Roch, Josiane Otto, J. Cadranel, (unknown), Denis Moro‐Sibilot, Thomas Egenod, R. Lamy, Jaafar Bennouna, Gérard Zalcman, Charles Ricordel, (unknown), (unknown), Benjamin Besse, (unknown), Virginie Westeel, Simon Baldacci	1
10	1303P Lorlatinib for advanced ALK+ non-small cell lung cancer (NSCLC): Efficacy and safety data from IFCT-1803 LORLATU expanded access program (EAP) cohort 2020 ·Annals of Oncology ·Simon Baldacci, Benjamin Besse, Virginie Avrillon, B. Mennecier, Pascale Dubray‐Longeras, Julien Mazières, R. Descourt, M. Duruisseaux, Xavier Quantin, H. Doubre, I. Monnet, Denis Moro‐Sibilot, S. Schneider, Sophie Cousin, P. Merle, Josiane Otto, Alexandra Langlais, Franck Morin, Virginie Westeel, Nicolas Girard	1
11	Combining EGFR and MET Inhibition With Crizotinib in EGFR-mutated Lung Adenocarcinoma Harboring MET Amplification: A Brief Report 2020 ·Clinical Lung Cancer ·(unknown), Aurélie Swalduz, Virginie Avrillon, (unknown), Bénédicte Mastroïanni, Eve‐Marie Neidhardt‐Berard, M. Pérol	3
12	Les CBNPC de stades avancés hors addiction oncogénique: les traitements systémiques de deuxième ligne 2019 ·Revue des Maladies Respiratoires Actualités ·M. Pérol, (unknown), Alexis B. Cortot, Pierre Jean Souquet, Aurélie Swalduz, Virginie Avrillon	1
13	Implementing flexible bronchoscopy in least developed countries according to international guidelines is feasible and sustainable: example from Phnom-Penh, Cambodia 2017 ·BMC Pulmonary Medicine ·(unknown), S. Couraud, (unknown), (unknown), (unknown), Virginie Avrillon, Pierre-Jean Souquet, (unknown)	1
14	Évaluation d’un auto-questionnaire de repérage des expositions professionnelles chez les patients atteints de cancer bronchopulmonaire 2017 ·Bulletin du Cancer ·Mélanie Varin, Barbara Charbotel, Olivia Pérol, Lionel Perrier, Amélie Massardier-Pilonchery, (unknown), (unknown), Emmanuel Fort, Virginie Avrillon, Paul Rebattu, M. Pérol, (unknown)	8
15	Clinical relevance of ROS1 rearrangements detection in advanced squamous cell carcinomas 2016 ·Lung Cancer ·(unknown), Virginie Avrillon, Arnaud de la Fouchardière, (unknown), Sylvie Lantuéjoul, Jérôme Fayette	6
16	Lung Cancer May Increase Serum Procalcitonin Level 2015 ·Infectious Disorders - Drug Targets ·Virginie Avrillon, M. Locatelli-Sanchez, Laure Folliet, (unknown), (unknown), Gaëlle Fossard, (unknown), N. Freymond, L. Gérinière, (unknown), Pierre-Jean Souquet, S. Couraud	33
17	Comment appliquer les recommandations de bonnes pratiques dans les pays pauvres ? L’exemple de la mise en place d’une unité d’endoscopie bronchique au Cambodge 2013 ·Revue de Pneumologie Clinique ·S. Couraud, S. Chan, Virginie Avrillon, K. Horn, (unknown), L. Gérinière, (unknown), (unknown), (unknown), (unknown)	1
18	Life-threatening disseminated tuberculosis as a complication of treatment by infliximab for Crohn's disease: report of two cases, including cerebral tuberculomas and miliary tuberculosis 2012 ·Journal of Crohn s and Colitis ·Claire Tissot, S. Couraud, (unknown), Philippe Girard, Virginie Avrillon, L. Gérinière, (unknown), Pierre-Jean Souquet	7
19	Aspergillose pulmonaire chronique nécrosante compliquant une pneumopathie à Mycobacterium malmoense 2012 ·Revue des Maladies Respiratoires ·(unknown), C. Prost, S. Couraud, (unknown), G. Carret, A. Boibieux, Marie Claude Gagnieu, L. Gérinière, Virginie Avrillon, P.-J. Souquet	1
20	Carcinome bronchioloalvéolaire et transplantation pulmonaire 2011 ·Revue des Maladies Respiratoires ·Virginie Avrillon, F. Philit, Lara Chalabreysse, (unknown), F. Tronc, F. Thivolet-Béjui, (unknown)	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact